None listed
Conditions
Interventions
Dietary Supplement : Consume 500 mg/day of Theracurmin CR-033P as Test Food 1, 400 mg/day of Theracurmin super TS-P1 as Test Food 2, and Placebo as a control food. A total of 3 groups will take 2 caps
Sponsors
Seoul National University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Healthy adult males and females between the ages of 30 and 59 years. 2) The people who agree to participate in this human clinical trial and complete a written informed consent form before the start of the human clinical trial.
Exclusion criteria
Exclusion criteria: 1) Have or are currently being treated for a serious cardiovascular, immune, respiratory, gastrointestinal/liver and biliary, renal and urinary, neurologic, musculoskeletal, psychiatric, or infectious disease 2) Diagnosed with thyroid disease diabetes and currently taking related medications 3) Have had a surgical procedure within 6 months of Visit 1 4) Unable to perform treadmill exercise 5) Maximal oxygen uptake (VO2 max) in the exercise is greater than or equal to grade 1 for their age group 6) Continued regular exercise within 3 months prior to Visit 1 (3 or more days per week, 30 minutes or more of exertion per day). 7) BMI less than or equal to 18 kg/m2 and greater than or equal to 30 kg/m2 8) Those who score 47.7 or more in the balance category and 67.3 or more in the variety category on the Nutrition Index Questionnaire. 9) Excessive alcohol consumers (420 g/week or more: about 7 bottles/week, 1 bottle/day based on soju) or alcoholics 10) Smokers, Drug addicts (However, those who have quit smoking for more than 1 year as of Visit 1 are eligible to participate. 11) Subjects who have taken nutritional supplements (vitamins, amino acids, creatine, protein drinks, etc.) within 2 months prior to Visit 1. 12) Use of dietary supplements (red ginseng, chlorella, green tea extract, spirulina, propolis extract, coenzyme Q10, squalene, tomato extract, etc.) or medications (lipid-lowering, anti-inflammatory, blood pressure-lowering, antibiotics, aspirin, anti-inflammatory, blood glucose-lowering, anticoagulants, steroids, etc.) and chinese medicine 13) Subjects with uncontrolled hypertension (systolic blood pressure greater than or equal to 140 mmHg or diastolic blood pressure greater than or equal to 100 mmHg, measured after 10 minutes of subject rest) 14) Subjects who have lost more than 4 kg of body weight within 1 month of Visit 1 15) Pregnant or lactating women or those planning to become pregnant during the course of this human study 16) Participation in another interventional clinical trial (including human clinical trials) within 3 months of Visit 1, or plans to participate in another interventional clinical trial (including human clinical trials) after the start of this human clinical trial. 17) Subjects who are sensitive or allergic to any of the food ingredients in this human clinical trial. 18) Subjects deemed unsuitable by the investigator for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy (CAT activity, TOS&TAS etc.) | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety (Checking for adverse effects, Hemoglobin, AST (GOT), ALT(GPT), Blood pressure, Pulse etc.) | — |
Countries
Korea, Republic of
Contacts
Public ContactWook Song
Seoul National University
Outcome results
None listed